Sosei Heptares Receives Commitment from JIC Venture Growth Investments, an Affiliate of Japan Investment Corporation (JIC), to Conditionally Invest JPY 8 Billion (approx. US$54 Million) from New OPF1 Fund
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
(Correction) Partial corrections of “Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan”
Sosei Heptares announces nomination of new disease target by Takeda under strategic multi-target research, development and commercialization partnership
Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19
Presentation and Webcast - Sosei Heptares and Neurocrine Biosciences Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Sosei Heptares and Neurocrine Biosciences Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
Sosei Heptares notes presentation of post hoc analysis showing high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
Sosei Heptares notes publication of Phase III IRIDIUM data in The Lancet Respiratory Medicine showing benefit of Enerzair® Breezhaler® (QVM149) in uncontrolled asthma
Sosei Heptares announces new publication highlighting the potential of structure-based approaches to generate novel peptide-based drugs targeting GPCRs
Sosei Heptares notes the announcement of positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Sosei Heptares to receive new $3 million milestone payment from Pfizer, as it advances a second candidate from the GPCR collaboration for clinical development
Sosei Heptares notes that a valid Marketing Authorization Application for QVM149, a potential new inhaled combination therapy for asthma, has been filed with the European Medicines Agency
Sosei Heptares notes abstracts and posters reporting clinical and preclinical data from studies with immuno-oncology candidate AZD4635, presented by AstraZeneca at AACR 2019, are available
Sosei Heptares to introduce Restricted Share Units and Performance Share Units as new share-based incentive plans - Creating a globally consistent share-based incentive plan to encourage and reward corporate growth and better align with shareholders
Sosei Heptares to Host Town Hall Meetings for Individual Shareholders in Nagoya and Osaka - Shinichi Tamura, Chairman and CEO, and Chris Cargill, CFO, to present
Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0030310, a selective SSTR5 (somatostatin 5) receptor agonist in development to treat endocrine disorders
Sosei Heptares notes that MiNA Therapeutics has started enrolment of patients with advanced liver cancer in Phase 1b trial of MTL-CEBPA in combination with sorafenib
Sosei Heptares starts new clinical development program – First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Sosei’s Strategic Minority Investment Company, MiNA Therapeutics, Announces Update From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
Sosei confirms new data demonstrating AZD4635, a novel A2A receptor antagonist, induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models
Sosei subsidiary, Heptares, enters drug R&D collaboration with Imperial College London focused on multiple GPCR disease target opportunities in the gastro-intestinal tract
Sosei Subsidiary Heptares Enters a New Research and Drug Discovery Collaboration under its “ORBIT” Initiative with New York University School of Medicine
Sosei Subsidiary Heptares’ Co-Founder and Chief Scientific Officer, Fiona MARSHALL, Receives 2017 John Daily Lecture Award in Recognition of Her Outstanding Contribution to GPCR Drug Discovery
Sosei Subsidiary Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders
Sosei subsidiary Heptares announces positive results from Phase 1b clinical trial with HTL9936, a first-in-class selective muscarinic M1 receptor agonist for improving cognition in dementia and schizophrenia
Sosei confirms FDA approvals of new dual combination bronchodilator Utibron Neohaler and monotherapy Seebri™ Neohaler® for patients with chronic obstructive pulmonary disease
The UK BioIndustry Association (BIA) published a new report, Celebrating UK bioscience: unravelling the stories behind UK bioscience success, in which it highlights the background to and the importance of the Heptares StaR® technology.
Sosei subsidiary Heptares announces positive outcome of Phase 1a study with first-ever selective muscarinic M1 receptor agonist for improving cognition in patients with Alzheimer’s disease
Sosei Subsidiary Heptares launches ORBIT, a new collaborative R&D initiative designed to promote and broaden the application of its proprietary structure-based drug design expertise directed at G protein-coupled receptors (GPCRs)
Positive results from three clinical trials presented at ERS 2014 further confirmed efficacy of Ultibro® Breezhaler® and Seebri® Breezhaler®, and promotion agreement with Pfizer in the UK
Once-daily Ultibro® Breezhaler® showed superior efficacy versus Seretide® for COPD patients in second head-to-head study, and the anticipated timing of China filing
First in class once-daily dual bronchodilator QVA149 gains endorsement for approval from Drug Committee of MHLW (Ministry of Health, Labour and Welfare) for the treatment of COPD in Japan
NVA237 Phase II results presented at the European Respiratory Society Annual Meeting show promising efficacy and tolerability with potentially faster onset than tiotropium.
Sosei announces the launch of its US company targeting the development of CNS compounds. Deal with Mitsubishi Pharma Corporation provides the platform.